"Comparison of Outcomes Between Intracytoplasmic Sperm Injection and In Vitro Fertilization with Pre-implantation Genetic Testing for Aneuploidy, Analysis of SART CORS Data".

To evaluate whether insemination via intracytoplasmic sperm injection provides any benefit over in vitro fertilization for non-male factor infertility with respect to pre-implantation genetic testing results and pregnancy outcome. Retrospective Cohort Study of the Society for Assisted Reproductive Technology database. Patients undergoing in vitro fertilization or intracytoplasmic sperm injection in non-male factor pre-implantation genetic testing for aneuploidy cycles. In vitro fertilization vs. intracytoplasmic sperm injection MAIN OUTCOME MEASURES: Primary outcomes were percentage of embryos suitable for transfer and live birth rates. Secondary outcomes included subgroup analysis for embryos suitable for transfer on cycles from patients ≥ 35 y/o vs. < 35 y/o, ≤ 6 oocytes retrieved vs. > 6 oocytes retrieved, and unexplained infertility. Additionally, gestational age at delivery and birthweight between in vitro fertilization and intracytoplasmic sperm injection were evaluated. A total of 30,446 non-male factor preimplantation genetic diagnosis for aneuploidy cycles were evaluated, of which 4867 were in vitro fertilization and 25,579 were intracytoplasmic sperm injection. Following exclusion criteria and adjustment for any necessary confounding variables, no significant differences existed in embryos suitable for transfer between in vitro fertilization and intracytoplasmic sperm injection cycles, 41.6% (40.6%, 42.6%) vs. 42.5% (42.0%, 42.9%), respectively or live birth rates, 50.1% (37.8, 62.4%) vs. 50.8% (38.5%, 62.9%), respectively. There were no significant differences in the rates of embryos suitable for transfer and live birth rates between in vitro fertilization and intracytoplasmic sperm injection in non-male factor cycles undergoing pre-implantation genetic testing for aneuploidy.

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.